Solid cancer: the new tumour spread endpoint opens novel opportunities
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu úvodníky, práce podpořená grantem
PubMed
31427682
PubMed Central
PMC6889500
DOI
10.1038/s41416-019-0536-0
PII: 10.1038/s41416-019-0536-0
Knihovny.cz E-zdroje
- MeSH
- antagonisté androgenů terapeutické užití MeSH
- benzamidy MeSH
- chemorezistence genetika MeSH
- doba přežití bez progrese choroby MeSH
- fenylthiohydantoin analogy a deriváty terapeutické užití MeSH
- lidé MeSH
- metastázy nádorů diagnostické zobrazování prevence a kontrola MeSH
- nádory prostaty rezistentní na kastraci krev diagnostické zobrazování farmakoterapie patologie MeSH
- nitrily MeSH
- pohyb buněk účinky léků MeSH
- progrese nemoci MeSH
- proliferace buněk účinky léků MeSH
- prostatický specifický antigen krev MeSH
- pyrazoly terapeutické užití MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- testosteron krev MeSH
- thiohydantoiny terapeutické užití MeSH
- tumor burden účinky léků MeSH
- Úřad Spojených států pro potraviny a léky MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
- úvodníky MeSH
- Geografické názvy
- Spojené státy americké MeSH
- Názvy látek
- antagonisté androgenů MeSH
- apalutamide MeSH Prohlížeč
- benzamidy MeSH
- darolutamide MeSH Prohlížeč
- enzalutamide MeSH Prohlížeč
- fenylthiohydantoin MeSH
- nitrily MeSH
- prostatický specifický antigen MeSH
- pyrazoly MeSH
- testosteron MeSH
- thiohydantoiny MeSH
Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced imaging. Past failures are the likely result of equating tumour shrinkage to efficacy, rather than inhibition of tumour spread. In the future, the selection of anti-metastasis drug candidates will probably be based on anti-migratory rather than anti-proliferative potential. Oligometastatic cancer coupled with advanced imaging can serve as a clinical proof-of-concept model.
Zobrazit více v PubMed
Beaver JA, Kluetz PG, Pazdur R. Metastasis-free Survival—a new end point in prostate cancer trials. N. Engl. J. Med. 2018;378:2458–2460. doi: 10.1056/NEJMp1805966. PubMed DOI
U.S. Department of Health and Human Services. Food and Drug Administration. Draft Guidance. Nonmetastatic, castration resistant prostate cancer: considerations for metastasis-free survival endpoint in clinical trials. 2018. https://www.fda.gov/media/117792/download
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. for the SPARTAN investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 2018;378:1408–1418. doi: 10.1056/NEJMoa1715546. PubMed DOI
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 2018;378:2465–2474. doi: 10.1056/NEJMoa1800536. PubMed DOI PMC
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 2019;380:1235–1246. doi: 10.1056/NEJMoa1815671. PubMed DOI
Brábek J, Rosel D, Fernandes M. Pragmatic medicine in solid cancer: a translational alternative to precision medicine. Onco Targets Ther. 2016;9:1839–1855. doi: 10.2147/OTT.S103832. PubMed DOI PMC
Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, et al. Migrastatics-anti-metastatic and anti-invasion drugs: promises and challenges. Trends Cancer. 2017;3:391–406. doi: 10.1016/j.trecan.2017.04.008. PubMed DOI PMC
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 2011;8:378–382. doi: 10.1038/nrclinonc.2011.44. PubMed DOI
Hong JC, Salama JK. The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? Cancer Treat. Rev. 2017;52:22–32. doi: 10.1016/j.ctrv.2016.11.003. PubMed DOI
Leung L, Niculescu-Duvaz D, Smithen D, Lopes F, Callens C, McLeary R, et al. Anti-metastatic inhibitors of lysyl oxidase (LOX): design and structure-activity relationships. J. Med. Chem. 2019;62:5863–5884. doi: 10.1021/acs.jmedchem.9b00335. PubMed DOI PMC
Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblätter M, et al. The beginning of the end for conventional RECIST—novel therapies require novel imaging approaches. Nat. Rev. Clin. Oncol. 2019;16:442–458. doi: 10.1038/s41571-019-0169-5. PubMed DOI
Fendler Wolfgang P., Calais Jeremie, Eiber Matthias, Flavell Robert R., Mishoe Ashley, Feng Felix Y., Nguyen Hao G., Reiter Robert E., Rettig Matthew B., Okamoto Shozo, Emmett Louise, Zacho Helle D., Ilhan Harun, Wetter Axel, Rischpler Christoph, Schoder Heiko, Burger Irene A., Gartmann Jeannine, Smith Raven, Small Eric J., Slavik Roger, Carroll Peter R., Herrmann Ken, Czernin Johannes, Hope Thomas A. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology. 2019;5(6):856. doi: 10.1001/jamaoncol.2019.0096. PubMed DOI PMC
Hoffmann Manuela A., Wieler Helmut J., Baues Christian, Kuntz Nicholas J., Richardsen Ines, Schreckenberger Mathias. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. Urology. 2019;130:1–12. doi: 10.1016/j.urology.2019.04.004. PubMed DOI
Brábek J, Fernandes M. Affordable cancer care. Lancet Oncol. 2012;1:32–33. PubMed
